These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 26879132)
1. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer. Schmid G; Notaro S; Reimer D; Abdel-Azim S; Duggan-Peer M; Holly J; Fiegl H; Rössler J; Wiedemair A; Concin N; Altevogt P; Marth C; Zeimet AG BMC Cancer; 2016 Feb; 16():102. PubMed ID: 26879132 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers. Notaro S; Reimer D; Fiegl H; Schmid G; Wiedemair A; Rössler J; Marth C; Zeimet AG BMC Cancer; 2016 Aug; 16():589. PubMed ID: 27485273 [TBL] [Abstract][Full Text] [Related]
3. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues]. Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095 [TBL] [Abstract][Full Text] [Related]
4. Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Reimer D; Hubalek M; Kiefel H; Riedle S; Skvortsov S; Erdel M; Hofstetter G; Concin N; Fiegl H; Müller-Holzner E; Marth C; Altevogt P; Zeimet AG Oncogene; 2011 Sep; 30(38):4038-49. PubMed ID: 21516127 [TBL] [Abstract][Full Text] [Related]
5. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Vogt M; Munding J; Grüner M; Liffers ST; Verdoodt B; Hauk J; Steinstraesser L; Tannapfel A; Hermeking H Virchows Arch; 2011 Mar; 458(3):313-22. PubMed ID: 21225432 [TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of miR-34a contributes to the risk, progression, metastasis and poor survival of laryngeal squamous cell carcinoma. Shen Z; Zhou C; Li J; Ye D; Li Q; Wang J; Cui X; Chen X; Bao T; Duan S Gene; 2016 Nov; 593(2):272-6. PubMed ID: 27450916 [TBL] [Abstract][Full Text] [Related]
7. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression. Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093 [TBL] [Abstract][Full Text] [Related]
8. Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma. Cui X; Zhao Z; Liu D; Guo T; Li S; Hu J; Liu C; Yang L; Cao Y; Jiang J; Liang W; Liu W; Li S; Wang L; Wang L; Gu W; Wu C; Chen Y; Li F J Exp Clin Cancer Res; 2014 Feb; 33(1):20. PubMed ID: 24528540 [TBL] [Abstract][Full Text] [Related]
9. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529 [TBL] [Abstract][Full Text] [Related]
10. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis. Loginov VI; Pronina IV; Burdennyy AM; Filippova EA; Kazubskaya TP; Kushlinsky DN; Utkin DO; Khodyrev DS; Kushlinskii NE; Dmitriev AA; Braga EA Gene; 2018 Jul; 662():28-36. PubMed ID: 29631007 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia. Ng HY; Wan TS; So CC; Chim CS J Clin Pathol; 2014 Jul; 67(7):626-31. PubMed ID: 24811488 [TBL] [Abstract][Full Text] [Related]
12. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Lodygin D; Tarasov V; Epanchintsev A; Berking C; Knyazeva T; Körner H; Knyazev P; Diebold J; Hermeking H Cell Cycle; 2008 Aug; 7(16):2591-600. PubMed ID: 18719384 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis. Javeri A; Ghaffarpour M; Taha MF; Houshmand M Med Oncol; 2013 Mar; 30(1):413. PubMed ID: 23292869 [TBL] [Abstract][Full Text] [Related]
14. miR-34a inhibits the in vitro cell proliferation and migration in human esophageal cancer. Shi H; Zhou S; Liu J; Zhu J; Xue J; Gu L; Chen Y Pathol Res Pract; 2016 May; 212(5):444-9. PubMed ID: 26944831 [TBL] [Abstract][Full Text] [Related]
15. The association between miR-34 dysregulation and distant metastases formation in lung adenocarcinoma. Daugaard I; Knudsen A; Kjeldsen TE; Hager H; Hansen LL Exp Mol Pathol; 2017 Jun; 102(3):484-491. PubMed ID: 28512015 [TBL] [Abstract][Full Text] [Related]
16. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Gallardo E; Navarro A; Viñolas N; Marrades RM; Diaz T; Gel B; Quera A; Bandres E; Garcia-Foncillas J; Ramirez J; Monzo M Carcinogenesis; 2009 Nov; 30(11):1903-9. PubMed ID: 19736307 [TBL] [Abstract][Full Text] [Related]
17. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors. Czekierdowski A; Czekierdowska S; Danilos J; Czuba B; Sodowski K; Sodowska H; Szymanski M; Kotarski J J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():53-65. PubMed ID: 18955754 [TBL] [Abstract][Full Text] [Related]
18. Characterization of a p53/miR-34a/CSF1R/STAT3 Feedback Loop in Colorectal Cancer. Shi X; Kaller M; Rokavec M; Kirchner T; Horst D; Hermeking H Cell Mol Gastroenterol Hepatol; 2020; 10(2):391-418. PubMed ID: 32304779 [TBL] [Abstract][Full Text] [Related]
19. Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer. Xie K; Liu J; Chen J; Dong J; Ma H; Liu Y; Hu Z Gene; 2014 Jun; 543(1):101-7. PubMed ID: 24704024 [TBL] [Abstract][Full Text] [Related]
20. Evaluating L1CAM expression in human endometrial cancer using qRT-PCR. Notaro S; Reimer D; Duggan-Peer M; Fiegl H; Wiedermair A; Rössler J; Altevogt P; Marth C; Zeimet AG Oncotarget; 2016 Jun; 7(26):40221-40232. PubMed ID: 27233077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]